Mei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mei Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jie Zhang
Department of Nursing, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Lei Huang
Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, The First Affiliated Hospital of Naval Medical University/Changhai Hospital, Naval Medical University, Shanghai 200433, China; National Key Laboratory of Immunity and Inflammation, Changhai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University/Changhai Hospital, Naval Medical University, Shanghai 200433, China
2 shared publications Qianyun He
Department of Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
2 shared publicationsChen Wang
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication- Daqiao Zhu
School of Nursing, Shanghai Jiao Tong University, Shanghai, China
1 shared publication Dongliang Mao
Department of Nursing, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
Chemotherapy-induced hand-foot syndrome among Chinese inpatients: a qualitative descriptive study in Shanghai
Objective: To explore the symptom experiences and self-management strategies of patients with chemotherapy-induced hand-foot syndrome (HFS), and to identify approaches for improving symptom control and quality of life. Design: A qualitative study using semi-structured interviews and thematic analysis. Setting: We conducted this study in the oncology inpatient ward of a tertiary hospital in Shanghai, China. Participants: We used a purposive sampling approach to recruit 25 inpatients with chemotherapy-induced HFS from July 2022 to March 2024. The interviews were audio-recorded and transcribed verbatim. We employed an adapted version of Colaizzi’s qualitative analysis approach to examine the data. Results: 25 patients (mean age 58 years; 56% male) with grade I–III chemotherapy-induced HFS were interviewed. Four inter-related themes emerged. (1) Symptom experience: pain, numbness and burning sensations disturbed sleep; visible peeling and hyper-pigmentation triggered embarrassment and self-consciousness. (2) Emotional responses: most participants accepted symptoms as ‘part of treatment’, yet persistent anxiety about progression and guilt over becoming a family burden were common. (3) Social impact: patients avoided outdoor activities, stopped caring for grandchildren and reported lost income because ‘hands can’t touch cold or rough items’. (4) Future expectations: participants wanted pictorial self-care guides, a nurse hotline after discharge and earlier introduction of pain-relief strategies. All expressed frustration at ‘no-one to ask’ once home. Conclusions: Chemotherapy-induced HFS imposes a considerable multidimensional burden. Tailored, patient-centred interventions that integrate education, psychological support and family involvement are essential to improve symptom management and overall well-being. Future work should develop and test sustainable, long-term support strategies in broader populations. Scientific and clinical significance: This study provides the first qualitative evidence base for understanding and managing chemotherapy-induced HFS in Chinese patients, informing nurse-led interventions, patient-reported outcome development and national supportive-care policy.
Open AccessChemotherapy-induced hand-foot syndrome among Chinese inpatients: a qualitative descriptive study in Shanghai
Objective: To explore the symptom experiences and self-management strategies of patients with chemotherapy-induced hand-foot syndrome (HFS), and to identify approaches for improving symptom control and quality of life. Design: A qualitative study using semi-structured interviews and thematic analysis. Setting: We conducted this study in the oncology inpatient ward of a tertiary hospital in Shanghai, China. Participants: We used a purposive sampling approach to recruit 25 inpatients with chemotherapy-induced HFS from July 2022 to March 2024. The interviews were audio-recorded and transcribed verbatim. We employed an adapted version of Colaizzi’s qualitative analysis approach to examine the data. Results: 25 patients (mean age 58 years; 56% male) with grade I–III chemotherapy-induced HFS were interviewed. Four inter-related themes emerged. (1) Symptom experience: pain, numbness and burning sensations disturbed sleep; visible peeling and hyper-pigmentation triggered embarrassment and self-consciousness. (2) Emotional responses: most participants accepted symptoms as ‘part of treatment’, yet persistent anxiety about progression and guilt over becoming a family burden were common. (3) Social impact: patients avoided outdoor activities, stopped caring for grandchildren and reported lost income because ‘hands can’t touch cold or rough items’. (4) Future expectations: participants wanted pictorial self-care guides, a nurse hotline after discharge and earlier introduction of pain-relief strategies. All expressed frustration at ‘no-one to ask’ once home. Conclusions: Chemotherapy-induced HFS imposes a considerable multidimensional burden. Tailored, patient-centred interventions that integrate education, psychological support and family involvement are essential to improve symptom management and overall well-being. Future work should develop and test sustainable, long-term support strategies in broader populations. Scientific and clinical significance: This study provides the first qualitative evidence base for understanding and managing chemotherapy-induced HFS in Chinese patients, informing nurse-led interventions, patient-reported outcome development and national supportive-care policy.
- 4 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (6) , 1-11
Core symptoms in patients with colorectal cancer receiving chemotherapy: a network analysis
Objective To investigate the prevalence and intensity of symptoms in patients with colorectal cancer (CRC), and to develop a symptom network model to pinpoint key symptoms and clusters within the network. Methods This study encompassed 330 patients receiving postoperative treatment for CRC at a tertiary hospital's oncology department in Shanghai, China, from March 2023 to March 2024. Symptom assessment was conducted using the Chinese version of the MD Anderson Symptom Assessment Scale (MDASI-C) and a specially designed CRC module. Exploratory factor analysis was utilized to identify symptom clusters, and R 4.3.1 software was employed to construct networks of symptom severity and clusters. Centrality indicators, including strength, closeness, and betweenness, were subsequently analyzed to identify core symptoms and clusters. Results Among CRC symptoms, altered bowel habits were the most prevalent (n = 289, 87.6%), followed by distress (n = 250, 75.8%), pain (n = 244, 73.9%), weight loss (n = 205, 62.1%), and fatigue (n = 187, 56.7%). Three primary symptom clusters emerged: The gastrointestinal-neurological cluster, the sickness behavior cluster, and the emotional cluster (variance contribution rate, 36.8%, 19.0%, and 12.3%, respectively; cumulative, 68.1%). In the symptom severity network, numbness exhibited the highest expected influence (rE = 1.25); in the symptom cluster network, numbness (rs = 0.60), sadness (rs = 0.56), and fatigue (rs = 0.55) were the most influential symptoms across the three clusters. Conclusion In patients with CRC undergoing chemotherapy, network analysis identified numbness (gastrointestinal-neurological cluster), sadness (emotional cluster), and fatigue (sickness behavior cluster) as core symptoms, with numbness demonstrating the highest expected influence. The gastrointestinal-neurological cluster emerged as the most central. Strong symptom correlations (e.g., fear-sadness and numbness-sleep disturbance) underscored interconnected physical and psychological burdens. These findings advocate for prioritized targeted interventions: neurotoxicity monitoring for numbness, psychological support for emotional distress, and tailored fatigue management. A multidisciplinary approach is critical to address these interconnected clusters. Future research should employ longitudinal designs to unravel temporal symptom dynamics and refine personalized care.
- 4 June 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (6) , 1-11
Core symptoms in patients with colorectal cancer receiving chemotherapy: a network analysis
Objective To investigate the prevalence and intensity of symptoms in patients with colorectal cancer (CRC), and to develop a symptom network model to pinpoint key symptoms and clusters within the network. Methods This study encompassed 330 patients receiving postoperative treatment for CRC at a tertiary hospital's oncology department in Shanghai, China, from March 2023 to March 2024. Symptom assessment was conducted using the Chinese version of the MD Anderson Symptom Assessment Scale (MDASI-C) and a specially designed CRC module. Exploratory factor analysis was utilized to identify symptom clusters, and R 4.3.1 software was employed to construct networks of symptom severity and clusters. Centrality indicators, including strength, closeness, and betweenness, were subsequently analyzed to identify core symptoms and clusters. Results Among CRC symptoms, altered bowel habits were the most prevalent (n = 289, 87.6%), followed by distress (n = 250, 75.8%), pain (n = 244, 73.9%), weight loss (n = 205, 62.1%), and fatigue (n = 187, 56.7%). Three primary symptom clusters emerged: The gastrointestinal-neurological cluster, the sickness behavior cluster, and the emotional cluster (variance contribution rate, 36.8%, 19.0%, and 12.3%, respectively; cumulative, 68.1%). In the symptom severity network, numbness exhibited the highest expected influence (rE = 1.25); in the symptom cluster network, numbness (rs = 0.60), sadness (rs = 0.56), and fatigue (rs = 0.55) were the most influential symptoms across the three clusters. Conclusion In patients with CRC undergoing chemotherapy, network analysis identified numbness (gastrointestinal-neurological cluster), sadness (emotional cluster), and fatigue (sickness behavior cluster) as core symptoms, with numbness demonstrating the highest expected influence. The gastrointestinal-neurological cluster emerged as the most central. Strong symptom correlations (e.g., fear-sadness and numbness-sleep disturbance) underscored interconnected physical and psychological burdens. These findings advocate for prioritized targeted interventions: neurotoxicity monitoring for numbness, psychological support for emotional distress, and tailored fatigue management. A multidisciplinary approach is critical to address these interconnected clusters. Future research should employ longitudinal designs to unravel temporal symptom dynamics and refine personalized care.
- Open Access
- 7 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Continuous nursing symptom management in cancer chemotherapy patients using deep learning
To assess the efficacy of a deep learning platform for managing symptoms in chemotherapy patients, aiming to enhance their quality of life. A non-randomized controlled trial was conducted from September 2022 to March 2024, involving 144 chemotherapy patients divided into intervention (n = 72) and control (n = 72) groups. The intervention group received the deep learning platform, whereas the control group received standard care. Anxiety, depression, and quality of life were evaluated using the SAS, SDS, and QOL scores at baseline and after 6 months. Initial non-significant differences in SAS, SDS, and QOL scores between groups were observed. After intervention, significant improvements were noted in the intervention group for SAS, SDS, and various QOL aspects (P < 0.05). The platform received a high satisfaction score of 4.93 ± 0.13. The deep learning platform significantly reduced anxiety and depression and improved QOL in chemotherapy patients, demonstrating high patient satisfaction and potential for clinical application. Clinical trial registration: The trial was registered in clinical trials.gov with the registration number ChiCTR2400093540. The first registration date was 06/12/2024.
- 7 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessContinuous nursing symptom management in cancer chemotherapy patients using deep learning
To assess the efficacy of a deep learning platform for managing symptoms in chemotherapy patients, aiming to enhance their quality of life. A non-randomized controlled trial was conducted from September 2022 to March 2024, involving 144 chemotherapy patients divided into intervention (n = 72) and control (n = 72) groups. The intervention group received the deep learning platform, whereas the control group received standard care. Anxiety, depression, and quality of life were evaluated using the SAS, SDS, and QOL scores at baseline and after 6 months. Initial non-significant differences in SAS, SDS, and QOL scores between groups were observed. After intervention, significant improvements were noted in the intervention group for SAS, SDS, and various QOL aspects (P < 0.05). The platform received a high satisfaction score of 4.93 ± 0.13. The deep learning platform significantly reduced anxiety and depression and improved QOL in chemotherapy patients, demonstrating high patient satisfaction and potential for clinical application. Clinical trial registration: The trial was registered in clinical trials.gov with the registration number ChiCTR2400093540. The first registration date was 06/12/2024.
- Open Access
- 1 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy
Background: The liver is a key target organ for colorectal and gastric cancer metastasis. One of the challenges in the treatment of colorectal and gastric cancers is the management of liver metastasis. This study aimed to investigate the efficacy, adverse effects, and coping strategies of oncolytic virus injection in patients with liver metastases of gastrointestinal malignancies.Methods: We prospectively analyzed patients treated at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine from June 2021 to October 2022. 47 patients with gastrointestinal cancer liver metastasis were included in the study. The data, including clinical manifestations, imaging, tumor markers, postoperative adverse reactions, psychological intervention, dietary guidance, and adverse reaction management were evaluated.Results: Oncolytic virus injection was successful in all patients, and no drug injection-related deaths occurred. The adverse effects, such as fever, pain, bone marrow suppression, nausea, and vomiting, were mild and resolved subsequently. Based on the comprehensive intervention of nursing procedures, the postoperative adverse reactions of patients were effectively alleviated and treated. None of the 47 patients had any puncture point infections, and the pain caused by the invasive operation was relieved quickly. After 2 courses of oncolytic virus injection, postoperative liver MRI showed 5 partial remissions, 30 stable diseases, and 12 progressive diseases in target organs.Conclusion: Interventions based on nursing procedures can ensure the smooth treatment of recombinant human adenovirus type 5 in patients with liver metastases of gastrointestinal malignant tumors. This is of great importance for clinical treatment and significantly reduces patient complications and improves the patient’s quality of life.
- 1 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Open AccessEfficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy
Background: The liver is a key target organ for colorectal and gastric cancer metastasis. One of the challenges in the treatment of colorectal and gastric cancers is the management of liver metastasis. This study aimed to investigate the efficacy, adverse effects, and coping strategies of oncolytic virus injection in patients with liver metastases of gastrointestinal malignancies.Methods: We prospectively analyzed patients treated at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine from June 2021 to October 2022. 47 patients with gastrointestinal cancer liver metastasis were included in the study. The data, including clinical manifestations, imaging, tumor markers, postoperative adverse reactions, psychological intervention, dietary guidance, and adverse reaction management were evaluated.Results: Oncolytic virus injection was successful in all patients, and no drug injection-related deaths occurred. The adverse effects, such as fever, pain, bone marrow suppression, nausea, and vomiting, were mild and resolved subsequently. Based on the comprehensive intervention of nursing procedures, the postoperative adverse reactions of patients were effectively alleviated and treated. None of the 47 patients had any puncture point infections, and the pain caused by the invasive operation was relieved quickly. After 2 courses of oncolytic virus injection, postoperative liver MRI showed 5 partial remissions, 30 stable diseases, and 12 progressive diseases in target organs.Conclusion: Interventions based on nursing procedures can ensure the smooth treatment of recombinant human adenovirus type 5 in patients with liver metastases of gastrointestinal malignant tumors. This is of great importance for clinical treatment and significantly reduces patient complications and improves the patient’s quality of life.